Novus Therapeutics Inc
Change company Symbol lookup
Select an option...
NVUS Novus Therapeutics Inc
OCUL Ocular Therapeutix Inc
GOOG Alphabet Inc
BAC Bank of America Corp
ED Consolidated Edison Inc
FRAN Francesca's Holdings Corp
CWBHF Charlotte's Web Holdings Inc
SALM Salem Media Group Inc
ASML ASML Holding NV
FUN Cedar Fair LP
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.

Closing Price
$0.8906
Day's Change
0.0206 (2.37%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.94
Day's Low
0.831
Volume
(Light)
Volume:
1,725,348

10-day average volume:
17,322,331
1,725,348

Display:

Providers:

UpdateCancel
6 providers
September 15, 2020
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences

Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune and neurodegenerative diseases, today announced that...(BusinessWire)

Thinking about buying stock in Novus Therapeutics, Delta Air Lines, Sorrento Therapeutics, Carnival Corp, or Exela Technologies?

InvestorsObserver issues critical PriceWatch Alerts for NVUS, DAL, SRNE, CCL, and XELA. https://mma.prnewswire.com/media/1086590/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

September 14, 2020
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

--Senior management team with extensive drug development and commercialization experience, including Dr. David-Alexandre "DA" C. Gros as CEO and Dr. Steven Perrin as President and CSO, to lead Novus --Company completes private placement financing...(BusinessWire)

July 24, 2020
Global Otitis Media Pipeline Research Monitor 2020 with Profiles of 12 Companies Including Blue Water Vaccines, Lee's Pharma, Merck, Novus Therapeutics, and Yuhan Corp - ResearchAndMarkets.com

The "Otitis Media Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS (BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.